Innoviva 
Welcome,         Profile    Billing    Logout  
 14 Products   84 Diseases  14 Products   44 Trials   3538 News 
64 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
GCS 100 IV / Innoviva
ChiCTR-TRC-12002980: A randomized double-blind multicenter phase III study of Pegylated Human G-CSFin patients receiving myelosuppressive chemotherapy

Completed
3
510
 
GCSF 5ug/kg ;PEG-GCSF100ug/kg ;PEG-GCSF 6mg
Cancer Hospital of Chinese Academy of Medical Sciences; None, QILU PHARMACEUTICAL CO.LTD
Chemotherapy-induced neutropenia
 
 
2008-004087-40: A Phase 2 Study of GCS-100 in Combination with Chemo-immunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Ongoing
2
28
Europe
GCS-100, GCS-100,
Prospect Therapeutics, Inc
Relapsed or refractory diffuse large B-cell lymphoma
 
 
ChiCTR-TRC-12002499: Pharmacokinetics and Pharmacodynamics of Pegylated Human G-CSF

Completed
1/2
44
 
PEG-GCSF 60ug/kg ;PEG-GCSF100ug/kg ;PEG-GCSF 120ug/kg ;G-CSF 5ug/kg
Affiliated Beijing Chest Hospital of Capital Medical University; Beijing Chest Hospital, Capital Medical University, QILU PHARMACEUTICAL CO., LTD.
Chemotherapy-induced neutropenia
 
 
Breo Ellipta (fluticasone furoate / vilanterol) / GSK, Innoviva
2019-003864-27: Effect of inhalation formulation on uncontrolled asthma

Not yet recruiting
4
70
Europe
Flutiform K-haler, Relvar Ellipta, Inhalation solution, Inhalation powder, Flutiform K-haler, Relvar Ellipta
HUS / Mika Mäkelä, Mika Mäkelä
Asthma, Asthma, Diseases [C] - Respiratory Tract Diseases [C08]
 
 
2019-002744-24: An open clinical study to evaluate two inhaled treatments containing bronchodilators and cosrticosteroids on the market in terms of effects on some parts of the lungs in patients with chronic obstructive pulmonary disease through a user friendly innovative device

Not yet recruiting
4
36
Europe
TRIMBOW®, RELVAR® ELLIPTA®, Pressurised inhalation, solution, Inhalation powder, pre-dispensed, TRIMBOW®, RELVAR® ELLIPTA®
Chiesi Farmaceutici S.p.A.
Chronic Obstructive Pulmonary Disease (COPD), obstructive lung disease characterized by long-term breathing problems and poor airflow, Diseases [C] - Respiratory Tract Diseases [C08]
 
 
2011-005553-31: Study to evaluate the effectiveness of fluticasone furoate/vilanterol delivered once daily via a Novel Dry Powder Inhaler (NDPI) compared with existing Asthma maintenace therapy alone in subjects with Asthma.

Ongoing
3
4036
Europe
Fluticasone Furoate/GW642444 Inhalation Powder, Fluticasone Furoate/GW642444 Inhalation Powder, Inhalation powder, pre-dispensed, Relvar Ellipta
GlaxoSmithKline Research & Development Ltd, GlaxoSmithKline, Research and Development Ltd
Asthma, Asthma, Diseases [C] - Respiratory Tract Diseases [C08]
 
 
2010-019589-10: A Randomised, Double-Blind, Double-Dummy, Parallel-Group, Multicentre Study to assess efficacy and safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder and Fluticasone Propionate FP)/Salmeterol Inhalation Powder in the Treatment of Persistent Asthma in Adults and Adolescents.

Ongoing
3
62
Europe
Fluticasone Furoate/GW642444 Inhalation Powder, Seretide Accuhaler, FlixotideTM AccuhalerTM, Fluticasone Furoate/GW642444 Inhalation Powder, Seretide Accuhaler, FlixotideTM AccuhalerTM, Seretide Accuhaler, FlixotideTM AccuhalerTM
GlaxoSmithKline Research & Development Ltd
Persistent Asthma in Adults and Adolescents.
 
 
2011-002452-13: Study to evaluate the effectiveness of fluticasone furoate/vilanterol delivered once daily via a Novel Dry Powder Inhaler (NDPI) compared with existing COPD maintenance therapy alone in subjects with Chronic Obstructive Pulmonary Disease.

Ongoing
3
2798
Europe
Fluticasone Furoate/GW642444 Inhalation Powder, Fluticasone Furoate/GW642444 Inhalation Powder, Relvar Ellipta, Relvar Ellipta
GlaxoSmithKline Research & Development Ltd, GlaxoSmithKline, Research and Development Ltd
Subjects with Chronic Obstructive Pulmonary Disease (COPD).
 
 
2012-000927-42: Study of Fluticasone Furoate/Vilanterol in COPD, and the effects of Reducing Lung Over-Inflation on the Heart

Ongoing
3
50
Europe
Fluticasone Furoate/GW642444, Fluticasone Furoate/GW642444,
GlaxoSmithKline Research and Development Ltd, GSK
Chronic Obstructive Pulmonary Disease (COPD)
 
 
NCT04937387: Efficacy and Safety of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) in Chinese Participants With Inadequately Controlled Asthma

Completed
3
359
RoW
FF/VI, FF/UMEC/VI, ELLIPTA
GlaxoSmithKline
Asthma
08/24
08/24
NCT05757102: A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma

Recruiting
3
292
US, RoW
FF/UMEC/VI, ELLIPTA, FF/VI
GlaxoSmithKline
Asthma
01/27
01/27
NCT04265105: Fluticasone-Vilanterol Once Daily Dose for the Treatment of Mild Asthma in Adults

Completed
2/3
18
RoW
fluticasone-vilanterol, Standard Preparation, standard of care
Royal College of Surgeons in Ireland - Medical University of Bahrain
Asthma
01/23
01/23
2018-002529-48: Urine concentrations of vilanterol after inhaled administration of vilanterol/fluticasone furoate: Defining a urine threshold and decision limit for vilanterol in doping control analysis

Ongoing
2
26
Europe
Relvar Ellipta 22/184, Relvar Ellipta 184/22
Respiratory Research Unit, Bispebjerg Hospital, GlaxoSmithKline (GSK PHARMA)
Pharmacokinetics of vilanterol in relation to doping analysis Vilanterols farmakokinetik i relation til dopinganalyser., Pharmacokinetics of vilanterol in relation to doping analysis Vilanterols farmakokinetik i relation til dopinganalyser., Body processes [G] - Physiological processes [G07]
 
 
Giapreza (LJPC-501) / Innoviva
NCT05193370: Angiotensin II vs. Vasopressin in Septic Shock

Withdrawn
4
40
US
Angiotensin II, Giapreza, Vasopressin, Vasostrict
University of New Mexico, La Jolla Pharmaceutical Company, National Center for Advancing Translational Sciences (NCATS)
Septic Shock
11/22
11/22
NCT04904562: Angiotensin II for Distributive Shock

Recruiting
4
40
US
Angiotensin II, Giapreza, Placebo, Saline solution
Northwestern University, La Jolla Pharmaceutical Company
Distributive Shock
06/24
12/24
DARK-Sepsis, NCT05824767: Serum Biomarkers to Predict Response to Angiotensin II in Septic Shock

Completed
4
40
US
Angiotensin II, Giapreza
University of New Mexico, La Jolla Pharmaceutical Company
Septic Shock, Vasodilatory Shock
03/25
03/25
NCT03733145: Angiotensin II in General Anesthesia

Completed
4
31
US
Angiotensin II, Ang II, Giapreza
Wake Forest University Health Sciences, National Heart, Lung, and Blood Institute (NHLBI), National Institute on Aging (NIA)
Hypertension
03/23
03/23
NCT06122987: Hemodynamic Response to Angiotensin-II When Used as the Second Vasopressor Agent for Septic Shock

Recruiting
4
50
US
Angiotensin II and hydrocortisone sodium succinate, Giapreza
Kingman Regional Medical Center, La Jolla Pharmaceutical Company
Septic Shock, Shock, Sepsis, Systemic Inflammatory Response Syndrome
12/24
01/25
2021-003088-87: Reduction of occurence of Acute Kidney Injury through administration of angiotensin-II Reduktion des Auftretens einer akuten Nierenschädigung durch die Gabe von Glutamin

Not yet recruiting
3
64
Europe
Concentrate for solution for infusion, GIAPREZA 2.5 mg/ml concentrate for solution for infusion angiotensin II
Westfälische Wilhelms-Universität Münster, Deutsche Forschungsgemeinschaft
Cardiac surgical patients at high risk for AKI Herzchirurgische Patienten mit hohem Risiko für die Entwicklung einer AKI, Cardiac surgical patients at high risk for acute kidney injury Herzchirurgische Patienten mit einem hohen Risiko für die Entwicklung einer akuten Nierenschädigung, Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Therapeutic techniques [E02]
 
 
AngLT-1, NCT04901169: Angiotensin II in Liver Transplantation

Recruiting
2/3
50
US
Angiotensin II, Giapreza (synthetic human angiotensin II), Saline, 0.9% normal saline
University of California, San Francisco, La Jolla Pharmaceutical Company
Liver Transplant; Complications, Vasoplegia
09/25
09/26
NCT03623529 / 2017-005153-37: A Study of LJPC-501 in Paediatric Patients With Hypotension Associated With Distributive or Vasodilatory Shock

Recruiting
2
100
Europe
LJPC-501 (angiotensin II), Placebo, 0.9% sodium chloride solution
La Jolla Pharmaceutical Company
Catecholamine-resistant Hypotension (CRH), Distributive Shock, High Output Shock, Septic Shock
03/23
04/23
ANTHEM, NCT04048707: Angiotensin 2 for Hepatorenal Syndrome

Withdrawn
2
48
NA
Angiotensin II, Giapreza, Midodrine, Octreotide, Albumin solution
University of California, Los Angeles
Hepatorenal Syndrome, Cirrhosis, Kidney Failure, Acute
06/23
07/23
velusetrag (TD-5108) / Innoviva
NCT05724069 / 2021-000854-24: Velusetrag for the Treatment of Chronic Intestinal Pseudo-Obstruction (CIPO).

Completed
2
17
Europe
Velusetrag, Placebo
Alfasigma S.p.A., Alfasigma S.p.A.
Chronic Intestinal Pseudo-obstruction
04/23
04/23
2021-000854-24: Phase II multicenter clinical trial, with treatment randomly assigned, in which patient nor physician are aware of the assigned treatment, active or placebo, to evaluate efficacy and safety of Velusetrag 15 mg (3 x 5 mg capsule) in patients with Chronic Intestinal Pseudo-Obstruction (CIPO) Ensayo clínico multicéntrico de fase II, con tratamiento asignado aleatoriamente, en el que el paciente ni el médico conocen el tratamiento asignado, activo o placebo, para evaluar la eficacia y seguridad de Velusetrag 15 mg (3 cápsulas de 5 mg) en pacientes con pseudoobstrucción intestinal crónica (CIPO).

Not yet recruiting
2
16
Europe
Velusetrag, [TD-5108 hydrochloride], Capsule, hard
ALFASIGMA S.P.A., Alfasigma S.p.A.
Chronic intestinal pseudo-obstruction (CIPO) is a rare, severe condition characterized by an impairment of coordinated propulsive activity in the intestinal tract resulting in a clinical picture similar to that of mechanical intestinal obstruction, although in the absence of any lesion occluding the gut. CIPO can be idiopathic, when no primary underlying disorder is demonstrated, or secondary, when related to systemic diseases. La pseudoobstrucción intestinal crónica (CIPO) es una enfermedad rara y grave, caracterizada por una alteración de la actividad de propulsión coordinada en los intestinos que se traduce en un cuadro clínico parecido al de la obstrucción intestinal mecánica, salvo por la ausencia de lesiones que ocluyen el intestino. La CIPO puede ser idiopática, cuando no hay un trastorno primario subyacente demostrado, o secundaria, cuando está relacionada con enfermedades sistémicas., Chronic intestinal pseudo-obstruction (CIPO) is a rare disease impacting the intestinal motility, potentially invalidating. La pseudoobstrucción intestinal crónica (CIPO) es una enfermedad rara que afecta a la motilidad intestinal, potencialmente invalidante., Diseases [C] - Digestive System Diseases [C06]
 
 
zoliflodacin (ETX0914) / Global Antibiotic Research and Development Partnership, Innoviva
NCT03959527 / 2019-000990-22: Zoliflodacin in Uncomplicated Gonorrhoea

Completed
3
1011
Europe, US, RoW
zoliflodacin, ceftriaxone, azithromycin
Global Antibiotics Research and Development Partnership
Gonorrhea
08/23
09/23
NCT05635305: Zoliflodacin Bioequivalence and Drug-Drug Interaction Study

Completed
1
50
Europe
Zoliflodacin Patheon
Global Antibiotics Research and Development Partnership, Parexel, KCAS
Healthy Volunteers
02/23
02/23
Anoro Ellipta (umeclidinium/vilanterol) / Innoviva, GSK
ACTRN12621001503819: Inhaled Bronchodilators to support the use of Beta-Blockers in Chronic Obstructive Pulmonary Disease (COPD).

Not yet recruiting
4
36
 
Waikato District Health Board, Glaxo Smith Kline (GSK)
COPD, Cardiac Disease
 
 
CHHEF, NCT04522596 / 2019-004427-20: Effect of Dual Bronchodilation With Umeclidinium/Vilanterol on Patients With COPD, Hyperinflation and Heart Failure

Recruiting
4
60
Europe
Umeclidinium/vilanterol, Placebo
Luis Puente Maestu
Copd, Heart Failure
12/24
12/24
NCT06571942: Effect of the Inhaled Triple Therapies Over the Small Airway in Biomass Exposure

Recruiting
4
128
RoW
Vilanterol / Umeclidinium (25/62.5 mcg), ANORO, Fluthicasone / Vilanterol / Umeclidinium (100/25/62.5 mcg), TRELEGY, Beclomethasone / Formoterol / Glycopyrronyum 100/6/12.5 mcg, TRIMBOW, Budesonide / Formoterol / Glycopyrronyum 160/4.8/7.2 mcg, TRIXEO
National Institute of Respiratory Diseases, Mexico
COPD Bronchitis, Pollution Related Respiratory Disorder
01/25
01/25

Recruiting
4
1028
Europe
Trelegy Ellipta 100/62.5/25Mcg Inh 30D, LABA/LAMA/ICS, Brimica, LABA/LAMA, Duaklir, Ultibro, Ulunar, Xoterna, Anoro, Laventair, Spiolto Respimat, Yanimo, Foradil, LABA, Broncoral, Formoterol stada, Oxis, Formatris, Formoterol Aldo, Onbrez, Oslif, Hirobriz, Striverdi, Beglan, Betamican, Inaspir, Serevent, Soltel, Eklira, LAMA, Bretaris, Seebri, Tovanor, Enurev, Spiriva, Tavulus, Sirkava, Braltus, Gregal, Incruse, Rolufta
Fundacio Privada Mon Clinic Barcelona, GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
09/25
09/25
APIC, NCT06552364: Air Pollution and Inhaled Corticosteroids in COPD

Not yet recruiting
4
48
NA
LABA+LAMA, Anoro Ellipta, LABA+LAMA+ICS, Trelegy Ellipta, Filtered Air, Diesel Exhaust, Traffic Related Air Pollution
University of British Columbia, University of Calgary, University of Ottawa, University of Manitoba, University of North Carolina, Chapel Hill
COPD
12/26
12/28
NCT04536675: Effect of Perioperative Bronchodilator in COPD Patients Undergoing Lung Cancer Surgery

Recruiting
3
204
RoW
Vilanterol and Umeclidinium Bromide, Placebo
Samsung Medical Center
Chronic Obstructive Pulmonary Disease, Non Small Cell Lung Cancer
11/23
04/24
NCT06474039: The Efficacy of Fluticasone Furoate/Vilanterol/Umeclidinium Compared With Vilanterol/Umeclidinium in Reducing Air Trapping and Airway and Blood Cytokine Levels in COPD

Recruiting
3
50
RoW
Trelegy or Anoro
Mahidol University
COPD
06/26
12/26
2018-001722-25: This is a randomized, placebo-controlled, double−blind study meaning neither the patient nor the study doctor will know which medication is being given. The study is randomized, meaning that participants will be assigned to 1 of 3 treatment groups without any premeditated order. AZD8871 is administered once daily during two weeks in patients with moderate to severe COPD to evaluate its efficacy, how it is absorbed in the blood stream and its safety.

Not yet recruiting
2
72
Europe
AZD8871, Anoro® Ellipta® inhalation powder, AZD8871, Anoro® Ellipta® inhalation powder, Inhalation powder, Inhalation powder, pre-dispensed, Anoro®
AstraZeneca AB, AstraZeneca AB
Chronic Obstructive Pulmonary Disease (COPD), Moderate to severe COPD, Diseases [C] - Respiratory Tract Diseases [C08]
 
 
NCT03002389: Hyperpolarized Xenon-129 MRI: a New Multi-dimensional Biomarker to Determine Pulmonary Physiologic Responses to COPD Therapeutics

Active, not recruiting
2
95
US
Anoro Ellipta, umeclidinium + vilanterol, Arnuity Ellipta, fluticasone
University of Virginia
Chronic Obstructive Pulmonary Disease
12/23
01/28
Trelegy Ellipta (fluticasone furoate/umeclidinium bromide/vilanterol) / GSK, Innoviva, Theravance Biopharma
NCT05535972: To Evaluate Real-World Effectiveness of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol (FF/UMEC/VI) in a Single Inhaler (Trelegy Ellipta) in Participants With Symptomatic COPD

Completed
4
463
Europe, RoW
FF/UMEC/VI, TRELEGY ELLIPTA
GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
09/23
09/23
Sundial-COPD, NCT05292053: Outcomes of Once-Daily ICS/LABA/LAMA Plus PRN Respiratory Therapy Treatments in Hospitalized Patients With COPD Exacerbations

Not yet recruiting
4
80
US
TRELEGY ELLIPTA 100Mcg-62.5Mcg-25Mcg/Actuation Powder for Inhalation
Baylor Research Institute
Copd
08/23
09/23
NCT06372496: Pragmatic Open - Label Randomized Clinical Trial of FF/UMEC/VI vs Non-ellipta Usual Care ICS-LABA for Adult Participants With Uncontrolled Asthma

Active, not recruiting
4
1358
Canada, Japan, US, RoW
Fluticasone furoate/umeclidinium bromide/vilanterol trifenatate, Inhaled corticosteroids/long-acting beta-2 agonists
GlaxoSmithKline
Asthma
09/25
03/26
NCT04923347: A Study to Evaluate the Safety and Efficacy of Fluticasone Furoate (FF)/Umeclidinium(UMEC)/Vilanterol (VI) in Participants With Chronic Obstructive Pulmonary Disease (COPD)

Completed
4
229
RoW
FF/UMEC/VI, ELLIPTA
GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
03/24
03/24
NCT06905483: Comparative Effects of Triple Inhaled Therapy With Budesonide/Glycopyrronium/Formoterol Versus Fluticasone Furoate/Umeclidinium/Vilanterol on Small Airway Disease in COPD Patients: A Randomized Crossover Study

Recruiting
4
28
RoW
Budesonide/Glycopyrronium/Formoterol (BGF), Breztri, Fluticasone Furoate/Umeclidinium/Vilanterol (FUV), Trelegy
Thammasat University
COPD, Chronic Obstructive Pulmonary Disease (COPD), Small Airway Disease, Triple Therapy, Lung Function
12/25
03/26
2013-003075-35: A 12 month study to compare FF/UMEC/VI with FF/VI and UMEC/VI in patients with Chronic Obstructive Pulmonary Disease(COPD) and a history of COPD exacerbation

Ongoing
3
1000
Europe, RoW
Fluticasone Furoate/Umeclidinium/Vilanterol Trifenatate, Fluticasone Furoate/Vilanterol Trifenatate, Umeclidinium/Vilanterol Trifenatate, GSK2834425 (GW685698/GSK573719/GW642444), GW685698/GW642444, GSK573719/GW642444, Relvar Ellipta, Relvar Ellipta
GlaxoSmithKline Research & Development Ltd, GlaxoSmithKline, S.A., GlaxoSmithKline, Research and Development Ltd
Chronic Obstructive Pulmonary Disease (COPD)
 
 
2013-003073-10: A 24 week study (with an extension to 52 weeks in a proportion of subjects) to compare the safety and effectiveness of FF/UMEC/VI with budesonide/formoterol in subjects with COPD Studio di 24 settimane (con estensione a 52 settimane in un sottogruppo di soggetti) per confrontare la sicurezza e l’efficacia di FF/UMEC/VI vs. budesonide/formoterolo in soggetti con broncopneumopatia cronica ostruttiva.

Ongoing
3
200
Europe
Fluticasone Furoate/Umeclidinium/Vilanterol, SALBUTAMOLO, GSK2834425, SB-240563, Symbicort Turbohaler 400 micrograms/12 micrograms/inhalation, inhalation powder, VENTOLIN SOSP INAL 200D 100MCG, Symbicort Turbohaler 400 micrograms/12 micrograms/inhalation, inhalation powder, VENTOLIN SOSP INAL 200D 100MCG
GlaxoSmithKline Research and Development, GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
 
 
2017-001532-19: An open-label study to compare the effectiveness of FF/UMEC/VI using the Connected Inhaler System with FP/SAL plus tiotropium in participants with inadequately controlled asthma

Not yet recruiting
3
1006
Europe
Fluticasone Furoate/Umeclidinium/Vilanterol, (Seretide Accuhaler/DISKUS), Spiriva Respimat, GW685698/GSK573719/GW642444, R03AK06, Inhalation powder, pre-dispensed, Inhalation solution, Trelegy Ellipta, Seretide Accuhaler/Diskus, 250/50 mcg or 500/50mcg, Spiriva Respimat
GlaxoSmithKline Research & Development Ltd, GSK
Inadequately controlled asthma, Inadequately controlled asthma, Diseases [C] - Respiratory Tract Diseases [C08]
 
 
ETHA, NCT04651777: Evaluation of Triple Therapy Using Magnetic Resonance Imaging in Asthma

Active, not recruiting
3
31
Canada
FF/UMEC/VI, Trelegy
Dr. Grace Parraga, GlaxoSmithKline
Asthma
08/23
12/24
Xerava (eravacycline) / SOM Biotech, Ewha Womans University, PAION, Innoviva
TheraCRAB, NCT06440304: Therapeutic Options for CRAB

Recruiting
4
108
RoW
Fosfomycin, Fosfomycin with Colistin, Eravacycline, Eravacycline with Colistin, ampicillin/sulbactam, Ampicilin/sulbactam with Colistin
Clinical Hospital Centre Zagreb
Infections, Bacterial, Sepsis Bacterial
12/26
02/27
TREAT-GNB, NCT07004049: Optimising TREATment for Severe Gram-Negative Bacterial Infections

Recruiting
4
600
Europe, RoW
Colistin/Polymyxin B + Sulbactam, Colistin/Polymyxin B + Tigecycline/Eravacycline, Colistin/Polymyxin B + Meropenem, Ceftazidime-avibactam + Sulbactam, Ceftazidime-avibactam + Fosfomycin, Ceftazidime-avibactam, Ceftazidime-avibactam + Aztreonam, Ceftazidime-avibactam + Colistin/Polymyxin B, High-dose meropenem, Meropenem + Fosfomycin, Meropenem-vaborbactam, Cefiderocol, Ceftolozane-tazobactam, Ceftolozane-tazobactam + Meropenem
National University of Singapore, The University of Queensland, European Clinical Research Alliance for Infectious Diseases (ECRAID)
Bloodstream Infection, Ventilator Associated Bacterial Pneumonia, Hospital Acquired Bacterial Pneumonia, Carbapenem Resistant Bacterial Infection, Multidrug Resistance
12/28
12/28
ChiCTR2400087137: A study on the pharmacokinetic characteristics and penetration of Eravacycline in the pulmonary bronchial fluid of adult patients with hospital-acquired pneumonia or ventilator-associated pneumonia

Not yet recruiting
4
16
 
Eravacycline Hydrochloride for Injection; Eravacycline Hydrochloride for Injection; Eravacycline Hydrochloride for Injection; Eravacycline Hydrochloride for Injection
Huashan Hospital, Fudan University; Huashan Hospital, Fudan University, Funded by Everest Medicines for this IIT study
HAP or VAP
 
 
ChiCTR2500098643: An exploratory study on the efficacy of eravacycline in CRKP infection

Not yet recruiting
4
60
 
Elacycline combine with other commonly used clinical fungicides (such as meropenem, polycolistin E, polymyxin B, levofloxacin, ceftazobactam, piperac; Tigacycline combine with other commonly used clinical fungicides (such as meropenem, polycolistin E, polymyxin B, levofloxacin, ceftazo
Shanghai tenth People's Hospital; Shanghai tenth People's Hospital, Self-funded project
Intraperitoneal infection, bloodstream infection, pulmonary infection, urinary infection
 
 
ChiCTR1900022060: A Phase 3, Randomized, Multicenter, Double-Blind, Double-Dummy, Parallel-Group, Comparative Study to Assess the Efficacy, Safety and Tolerability of Eravacycline Versus Ertapenem in the Treatment of Complicated Intra-Abdominal Infections (cIAI) in Hospitalized Adults

Completed
3
160
 
Eravacycline 1.0 mg/kg IV q 12h ;Ertapenem 1g IV q 24h
West China Hospital, Sichuan University; Everest Medicines (US) Limited, Fully founded by sponsor
Complicated intra-abdominal infections
 
 
ChiCTR2300078646: Efficacy and safety of eravacycline for complicated intra-abdominal infections in the ICU: A multicenter, single-blind, parallel randomized controlled trial study

Recruiting
3
292
 
Intravenous eravacycline; Intravenous tigecycline
Ansteel Group General Hospital; Ansteel Group General Hospital, Health Development Promotion Project of Beijing Health Alliance Charitable Foundation
Complicated intra-abdominal infections
 
 
ChiCTR2200055666: A Phase II/III, Randomized, Two-stage Clinical Study to Assess the Efficacy, Safety and Tolerability of Eravacycline Versus Moxifloxacin in the Treatment of Community-acquired Bacterial Pneumonia (CABP) in Adult Subjects

Recruiting
2/3
520
 
Elacycline 1.0 mg/kg IV q 12 h ;Two doses of eracycline 1.5 mg/kg IV were administered 12 hours apart (q12h). From the second day to the end of treatment (the third dose to the final dose), elacycline was 1.5 mg/kg, q24h ;Elacycline (dose and frequency determined in Stage 1) ;Moxifloxacin 0.4 g IV q24h
China-Japan Friendship Hospital; Everest Medicines (US) Limited, self-funded
Community-acquired Bacterial Pneumonia
 
 
NCT06794541: A Study to Evaluate the Safety and Tolerability of Eravacycline in Pediatric Patients Aged 8 to 17 With Complicated Intra-abdominal Infections (cIAI)

Recruiting
2
35
US
Eravacycline 2mg/kg, Eravacycline 1.5mg/kg
Innoviva Specialty Therapeutics, Tetraphase Pharmaceuticals, Inc.
Complicated Intra-abdominal Infections (cIAI)
03/29
03/29
NCT05537896: Prospective Evaluation of Xerava Prophylaxis in Hematological Malignancy Patients With Prolonged Neutropenia

Recruiting
2
55
US
Eravacycline, Xerava
West Virginia University
Hematological Malignancy, Neutropenia
02/28
02/28
ChiCTR1900022906: A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Pharmacokinetics, Safety and Tolerability of Single-dose and Multiple-dose Intravenous Infusion of Eraracycline in Chinese Healthy Subjects

Completed
1
28
 
Eravacycline 0.5 mg/kg IV single dose ;Single dose: Eravacycline 1 mg/kg IV; Multiple dose: Eravacycline 1 mg/kg IV q12h, 10 days ;Eravacycline 2 mg/kg IV single dose
Huashan Hospital Affiliated to Fudan University; Everest Medicines (US) Limited, Fully founded by sponsor
Not applicable
 
 
NCT06282835: Eravacycline Combination Therapy for MRAB

Recruiting
N/A
20
RoW
Eravacycline Injection
Fujian Medical University Union Hospital
Pulmonary Infection, Pneumonia, Bacterial, Acinetobacter Baumannii
10/24
12/24
NCT06223100: Efficacy and Safety of the Combination Therapy Based on Eravacycline in Immunocompromised Hosts With MDROS Infection

Not yet recruiting
N/A
100
NA
Eravacycline, XERAVA
Sichuan Provincial People's Hospital
Immune Dysregulation Disorder
12/25
12/25
NCT06670872: A Study on the Combination Therapy of Eravacycline for Treating Carbapenem-Resistant Acinetobacter Baumannii Pneumonia

Not yet recruiting
N/A
50
RoW
Eravacycline combination therapy group
Peking University Third Hospital
Pneumonitis, Acinetobacter Baumannii
10/25
10/26
NCT06666998: Real-World Pharmacokinetic/Pharmacodynamic Study of Eravacycline in Critically III Patients

Not yet recruiting
N/A
100
NA
Sichuan Provincial People's Hospital
Eravacycline, Pharmacokinetics, Bacteria Infection, Bacterial Resistance to Antimicrobial, Empirical Antimicrobial Therapy
11/26
11/26
ChiCTR2400089338: The efficacy and safety observation study of Eravacycline treatment in patients with neutropenia and fever: A multicenter retrospective cohort study based on HIS data

Not yet recruiting
N/A
200
 
Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing Life Oasis Public Service Center
Granulocyte deficiency with fever
 
 
ChiCTR2400083038: A real-world study of the clinical use of eravacycline

Recruiting
N/A
50
 
None
Huashan hospital; Huashan hospital, Beijing Life Oasis public Service Center
Bacterial Infection
 
 
ChiCTR2500103344: Retrospective Study on the Efficacy and Safety of Eravacycline Based on Real-world Data

Not yet recruiting
N/A
300
 
NA
Sun Yat-sen Memorial Hospital, Sun Yat-sen University; Sun Yat-sen Memorial Hospital, Sun Yat-sen University, None
Patients clinically diagnosed with infections (including pulmonary infections, skin/soft tissue infections, intra-abdominal infections, bloodstream infections, etc.).
 
 
ChiCTR2500096976: Synergistic Mechanisms of Eravacycline Combined with Aminoglycosides in the Treatment of CRE Infections: A Single-Arm Clinical Study and Integrated Multi-Omics Analysis

Not yet recruiting
N/A
9
 
SUN YAT-SEN MEMORIAL HOSPITAL; SUN YAT-SEN MEMORIAL HOSPITAL, Primary Health Care Foundation of China
CRE infection
 
 
Xacduro (sulbactam-durlobactam) / Innoviva
NCT06801223: A Study to Assess Sulbactam-durlobactam in Pediatric Patients With Acinetobacter Baumannii-calcoaceticus Complex Infection

Recruiting
1
48
US
Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 6 hours), SUL-DUR, Sulbactam 20mg/kg-Durlobactam 20mg/kg (Every 8 hours), Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 8 hours), Sulbactam 20mg/kg-Durlobactam 20mg/kg (Every 12 hours)
Innoviva Specialty Therapeutics, Entasis Therapeutics
Acinetobacter Baumannii-calcoaceticus Complex Infection (ABC)
05/28
05/28
NCT06746883: A Study to Assess the Safety and Risk of Hypersensitivity Reactions of Sulbactam-durlobactam in Adults With Acinetobacter Baumannii-calcoaceticus (ABC) Complex Infection

Recruiting
N/A
100
US
Non-interventional
Innoviva Specialty Therapeutics
Acinetobacter Baumannii-calcoaceticus Complex Infection (ABC)
01/29
01/29
LJPC-401 / Innoviva
No trials found
LJP 1207 / Innoviva
No trials found
ETX1317 / Innoviva
No trials found
allopregnanolone (LJPC-0712) / Innoviva
No trials found
TP-2846 / Innoviva
No trials found
artesunate (LJPC-0118) / Innoviva
No trials found
cefpodoxime/ETX 1317 / Innoviva
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
GCS 100 IV / Innoviva
ChiCTR-TRC-12002980: A randomized double-blind multicenter phase III study of Pegylated Human G-CSFin patients receiving myelosuppressive chemotherapy

Completed
3
510
 
GCSF 5ug/kg ;PEG-GCSF100ug/kg ;PEG-GCSF 6mg
Cancer Hospital of Chinese Academy of Medical Sciences; None, QILU PHARMACEUTICAL CO.LTD
Chemotherapy-induced neutropenia
 
 
2008-004087-40: A Phase 2 Study of GCS-100 in Combination with Chemo-immunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Ongoing
2
28
Europe
GCS-100, GCS-100,
Prospect Therapeutics, Inc
Relapsed or refractory diffuse large B-cell lymphoma
 
 
ChiCTR-TRC-12002499: Pharmacokinetics and Pharmacodynamics of Pegylated Human G-CSF

Completed
1/2
44
 
PEG-GCSF 60ug/kg ;PEG-GCSF100ug/kg ;PEG-GCSF 120ug/kg ;G-CSF 5ug/kg
Affiliated Beijing Chest Hospital of Capital Medical University; Beijing Chest Hospital, Capital Medical University, QILU PHARMACEUTICAL CO., LTD.
Chemotherapy-induced neutropenia
 
 
Breo Ellipta (fluticasone furoate / vilanterol) / GSK, Innoviva
2019-003864-27: Effect of inhalation formulation on uncontrolled asthma

Not yet recruiting
4
70
Europe
Flutiform K-haler, Relvar Ellipta, Inhalation solution, Inhalation powder, Flutiform K-haler, Relvar Ellipta
HUS / Mika Mäkelä, Mika Mäkelä
Asthma, Asthma, Diseases [C] - Respiratory Tract Diseases [C08]
 
 
2019-002744-24: An open clinical study to evaluate two inhaled treatments containing bronchodilators and cosrticosteroids on the market in terms of effects on some parts of the lungs in patients with chronic obstructive pulmonary disease through a user friendly innovative device

Not yet recruiting
4
36
Europe
TRIMBOW®, RELVAR® ELLIPTA®, Pressurised inhalation, solution, Inhalation powder, pre-dispensed, TRIMBOW®, RELVAR® ELLIPTA®
Chiesi Farmaceutici S.p.A.
Chronic Obstructive Pulmonary Disease (COPD), obstructive lung disease characterized by long-term breathing problems and poor airflow, Diseases [C] - Respiratory Tract Diseases [C08]
 
 
2011-005553-31: Study to evaluate the effectiveness of fluticasone furoate/vilanterol delivered once daily via a Novel Dry Powder Inhaler (NDPI) compared with existing Asthma maintenace therapy alone in subjects with Asthma.

Ongoing
3
4036
Europe
Fluticasone Furoate/GW642444 Inhalation Powder, Fluticasone Furoate/GW642444 Inhalation Powder, Inhalation powder, pre-dispensed, Relvar Ellipta
GlaxoSmithKline Research & Development Ltd, GlaxoSmithKline, Research and Development Ltd
Asthma, Asthma, Diseases [C] - Respiratory Tract Diseases [C08]
 
 
2010-019589-10: A Randomised, Double-Blind, Double-Dummy, Parallel-Group, Multicentre Study to assess efficacy and safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder and Fluticasone Propionate FP)/Salmeterol Inhalation Powder in the Treatment of Persistent Asthma in Adults and Adolescents.

Ongoing
3
62
Europe
Fluticasone Furoate/GW642444 Inhalation Powder, Seretide Accuhaler, FlixotideTM AccuhalerTM, Fluticasone Furoate/GW642444 Inhalation Powder, Seretide Accuhaler, FlixotideTM AccuhalerTM, Seretide Accuhaler, FlixotideTM AccuhalerTM
GlaxoSmithKline Research & Development Ltd
Persistent Asthma in Adults and Adolescents.
 
 
2011-002452-13: Study to evaluate the effectiveness of fluticasone furoate/vilanterol delivered once daily via a Novel Dry Powder Inhaler (NDPI) compared with existing COPD maintenance therapy alone in subjects with Chronic Obstructive Pulmonary Disease.

Ongoing
3
2798
Europe
Fluticasone Furoate/GW642444 Inhalation Powder, Fluticasone Furoate/GW642444 Inhalation Powder, Relvar Ellipta, Relvar Ellipta
GlaxoSmithKline Research & Development Ltd, GlaxoSmithKline, Research and Development Ltd
Subjects with Chronic Obstructive Pulmonary Disease (COPD).
 
 
2012-000927-42: Study of Fluticasone Furoate/Vilanterol in COPD, and the effects of Reducing Lung Over-Inflation on the Heart

Ongoing
3
50
Europe
Fluticasone Furoate/GW642444, Fluticasone Furoate/GW642444,
GlaxoSmithKline Research and Development Ltd, GSK
Chronic Obstructive Pulmonary Disease (COPD)
 
 
NCT04937387: Efficacy and Safety of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) in Chinese Participants With Inadequately Controlled Asthma

Completed
3
359
RoW
FF/VI, FF/UMEC/VI, ELLIPTA
GlaxoSmithKline
Asthma
08/24
08/24
NCT05757102: A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma

Recruiting
3
292
US, RoW
FF/UMEC/VI, ELLIPTA, FF/VI
GlaxoSmithKline
Asthma
01/27
01/27
NCT04265105: Fluticasone-Vilanterol Once Daily Dose for the Treatment of Mild Asthma in Adults

Completed
2/3
18
RoW
fluticasone-vilanterol, Standard Preparation, standard of care
Royal College of Surgeons in Ireland - Medical University of Bahrain
Asthma
01/23
01/23
2018-002529-48: Urine concentrations of vilanterol after inhaled administration of vilanterol/fluticasone furoate: Defining a urine threshold and decision limit for vilanterol in doping control analysis

Ongoing
2
26
Europe
Relvar Ellipta 22/184, Relvar Ellipta 184/22
Respiratory Research Unit, Bispebjerg Hospital, GlaxoSmithKline (GSK PHARMA)
Pharmacokinetics of vilanterol in relation to doping analysis Vilanterols farmakokinetik i relation til dopinganalyser., Pharmacokinetics of vilanterol in relation to doping analysis Vilanterols farmakokinetik i relation til dopinganalyser., Body processes [G] - Physiological processes [G07]
 
 
Giapreza (LJPC-501) / Innoviva
NCT05193370: Angiotensin II vs. Vasopressin in Septic Shock

Withdrawn
4
40
US
Angiotensin II, Giapreza, Vasopressin, Vasostrict
University of New Mexico, La Jolla Pharmaceutical Company, National Center for Advancing Translational Sciences (NCATS)
Septic Shock
11/22
11/22
NCT04904562: Angiotensin II for Distributive Shock

Recruiting
4
40
US
Angiotensin II, Giapreza, Placebo, Saline solution
Northwestern University, La Jolla Pharmaceutical Company
Distributive Shock
06/24
12/24
DARK-Sepsis, NCT05824767: Serum Biomarkers to Predict Response to Angiotensin II in Septic Shock

Completed
4
40
US
Angiotensin II, Giapreza
University of New Mexico, La Jolla Pharmaceutical Company
Septic Shock, Vasodilatory Shock
03/25
03/25
NCT03733145: Angiotensin II in General Anesthesia

Completed
4
31
US
Angiotensin II, Ang II, Giapreza
Wake Forest University Health Sciences, National Heart, Lung, and Blood Institute (NHLBI), National Institute on Aging (NIA)
Hypertension
03/23
03/23
NCT06122987: Hemodynamic Response to Angiotensin-II When Used as the Second Vasopressor Agent for Septic Shock

Recruiting
4
50
US
Angiotensin II and hydrocortisone sodium succinate, Giapreza
Kingman Regional Medical Center, La Jolla Pharmaceutical Company
Septic Shock, Shock, Sepsis, Systemic Inflammatory Response Syndrome
12/24
01/25
2021-003088-87: Reduction of occurence of Acute Kidney Injury through administration of angiotensin-II Reduktion des Auftretens einer akuten Nierenschädigung durch die Gabe von Glutamin

Not yet recruiting
3
64
Europe
Concentrate for solution for infusion, GIAPREZA 2.5 mg/ml concentrate for solution for infusion angiotensin II
Westfälische Wilhelms-Universität Münster, Deutsche Forschungsgemeinschaft
Cardiac surgical patients at high risk for AKI Herzchirurgische Patienten mit hohem Risiko für die Entwicklung einer AKI, Cardiac surgical patients at high risk for acute kidney injury Herzchirurgische Patienten mit einem hohen Risiko für die Entwicklung einer akuten Nierenschädigung, Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Therapeutic techniques [E02]
 
 
AngLT-1, NCT04901169: Angiotensin II in Liver Transplantation

Recruiting
2/3
50
US
Angiotensin II, Giapreza (synthetic human angiotensin II), Saline, 0.9% normal saline
University of California, San Francisco, La Jolla Pharmaceutical Company
Liver Transplant; Complications, Vasoplegia
09/25
09/26
NCT03623529 / 2017-005153-37: A Study of LJPC-501 in Paediatric Patients With Hypotension Associated With Distributive or Vasodilatory Shock

Recruiting
2
100
Europe
LJPC-501 (angiotensin II), Placebo, 0.9% sodium chloride solution
La Jolla Pharmaceutical Company
Catecholamine-resistant Hypotension (CRH), Distributive Shock, High Output Shock, Septic Shock
03/23
04/23
ANTHEM, NCT04048707: Angiotensin 2 for Hepatorenal Syndrome

Withdrawn
2
48
NA
Angiotensin II, Giapreza, Midodrine, Octreotide, Albumin solution
University of California, Los Angeles
Hepatorenal Syndrome, Cirrhosis, Kidney Failure, Acute
06/23
07/23
velusetrag (TD-5108) / Innoviva
NCT05724069 / 2021-000854-24: Velusetrag for the Treatment of Chronic Intestinal Pseudo-Obstruction (CIPO).

Completed
2
17
Europe
Velusetrag, Placebo
Alfasigma S.p.A., Alfasigma S.p.A.
Chronic Intestinal Pseudo-obstruction
04/23
04/23
2021-000854-24: Phase II multicenter clinical trial, with treatment randomly assigned, in which patient nor physician are aware of the assigned treatment, active or placebo, to evaluate efficacy and safety of Velusetrag 15 mg (3 x 5 mg capsule) in patients with Chronic Intestinal Pseudo-Obstruction (CIPO) Ensayo clínico multicéntrico de fase II, con tratamiento asignado aleatoriamente, en el que el paciente ni el médico conocen el tratamiento asignado, activo o placebo, para evaluar la eficacia y seguridad de Velusetrag 15 mg (3 cápsulas de 5 mg) en pacientes con pseudoobstrucción intestinal crónica (CIPO).

Not yet recruiting
2
16
Europe
Velusetrag, [TD-5108 hydrochloride], Capsule, hard
ALFASIGMA S.P.A., Alfasigma S.p.A.
Chronic intestinal pseudo-obstruction (CIPO) is a rare, severe condition characterized by an impairment of coordinated propulsive activity in the intestinal tract resulting in a clinical picture similar to that of mechanical intestinal obstruction, although in the absence of any lesion occluding the gut. CIPO can be idiopathic, when no primary underlying disorder is demonstrated, or secondary, when related to systemic diseases. La pseudoobstrucción intestinal crónica (CIPO) es una enfermedad rara y grave, caracterizada por una alteración de la actividad de propulsión coordinada en los intestinos que se traduce en un cuadro clínico parecido al de la obstrucción intestinal mecánica, salvo por la ausencia de lesiones que ocluyen el intestino. La CIPO puede ser idiopática, cuando no hay un trastorno primario subyacente demostrado, o secundaria, cuando está relacionada con enfermedades sistémicas., Chronic intestinal pseudo-obstruction (CIPO) is a rare disease impacting the intestinal motility, potentially invalidating. La pseudoobstrucción intestinal crónica (CIPO) es una enfermedad rara que afecta a la motilidad intestinal, potencialmente invalidante., Diseases [C] - Digestive System Diseases [C06]
 
 
zoliflodacin (ETX0914) / Global Antibiotic Research and Development Partnership, Innoviva
NCT03959527 / 2019-000990-22: Zoliflodacin in Uncomplicated Gonorrhoea

Completed
3
1011
Europe, US, RoW
zoliflodacin, ceftriaxone, azithromycin
Global Antibiotics Research and Development Partnership
Gonorrhea
08/23
09/23
NCT05635305: Zoliflodacin Bioequivalence and Drug-Drug Interaction Study

Completed
1
50
Europe
Zoliflodacin Patheon
Global Antibiotics Research and Development Partnership, Parexel, KCAS
Healthy Volunteers
02/23
02/23
Anoro Ellipta (umeclidinium/vilanterol) / Innoviva, GSK
ACTRN12621001503819: Inhaled Bronchodilators to support the use of Beta-Blockers in Chronic Obstructive Pulmonary Disease (COPD).

Not yet recruiting
4
36
 
Waikato District Health Board, Glaxo Smith Kline (GSK)
COPD, Cardiac Disease
 
 
CHHEF, NCT04522596 / 2019-004427-20: Effect of Dual Bronchodilation With Umeclidinium/Vilanterol on Patients With COPD, Hyperinflation and Heart Failure

Recruiting
4
60
Europe
Umeclidinium/vilanterol, Placebo
Luis Puente Maestu
Copd, Heart Failure
12/24
12/24
NCT06571942: Effect of the Inhaled Triple Therapies Over the Small Airway in Biomass Exposure

Recruiting
4
128
RoW
Vilanterol / Umeclidinium (25/62.5 mcg), ANORO, Fluthicasone / Vilanterol / Umeclidinium (100/25/62.5 mcg), TRELEGY, Beclomethasone / Formoterol / Glycopyrronyum 100/6/12.5 mcg, TRIMBOW, Budesonide / Formoterol / Glycopyrronyum 160/4.8/7.2 mcg, TRIXEO
National Institute of Respiratory Diseases, Mexico
COPD Bronchitis, Pollution Related Respiratory Disorder
01/25
01/25

Recruiting
4
1028
Europe
Trelegy Ellipta 100/62.5/25Mcg Inh 30D, LABA/LAMA/ICS, Brimica, LABA/LAMA, Duaklir, Ultibro, Ulunar, Xoterna, Anoro, Laventair, Spiolto Respimat, Yanimo, Foradil, LABA, Broncoral, Formoterol stada, Oxis, Formatris, Formoterol Aldo, Onbrez, Oslif, Hirobriz, Striverdi, Beglan, Betamican, Inaspir, Serevent, Soltel, Eklira, LAMA, Bretaris, Seebri, Tovanor, Enurev, Spiriva, Tavulus, Sirkava, Braltus, Gregal, Incruse, Rolufta
Fundacio Privada Mon Clinic Barcelona, GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
09/25
09/25
APIC, NCT06552364: Air Pollution and Inhaled Corticosteroids in COPD

Not yet recruiting
4
48
NA
LABA+LAMA, Anoro Ellipta, LABA+LAMA+ICS, Trelegy Ellipta, Filtered Air, Diesel Exhaust, Traffic Related Air Pollution
University of British Columbia, University of Calgary, University of Ottawa, University of Manitoba, University of North Carolina, Chapel Hill
COPD
12/26
12/28
NCT04536675: Effect of Perioperative Bronchodilator in COPD Patients Undergoing Lung Cancer Surgery

Recruiting
3
204
RoW
Vilanterol and Umeclidinium Bromide, Placebo
Samsung Medical Center
Chronic Obstructive Pulmonary Disease, Non Small Cell Lung Cancer
11/23
04/24
NCT06474039: The Efficacy of Fluticasone Furoate/Vilanterol/Umeclidinium Compared With Vilanterol/Umeclidinium in Reducing Air Trapping and Airway and Blood Cytokine Levels in COPD

Recruiting
3
50
RoW
Trelegy or Anoro
Mahidol University
COPD
06/26
12/26
2018-001722-25: This is a randomized, placebo-controlled, double−blind study meaning neither the patient nor the study doctor will know which medication is being given. The study is randomized, meaning that participants will be assigned to 1 of 3 treatment groups without any premeditated order. AZD8871 is administered once daily during two weeks in patients with moderate to severe COPD to evaluate its efficacy, how it is absorbed in the blood stream and its safety.

Not yet recruiting
2
72
Europe
AZD8871, Anoro® Ellipta® inhalation powder, AZD8871, Anoro® Ellipta® inhalation powder, Inhalation powder, Inhalation powder, pre-dispensed, Anoro®
AstraZeneca AB, AstraZeneca AB
Chronic Obstructive Pulmonary Disease (COPD), Moderate to severe COPD, Diseases [C] - Respiratory Tract Diseases [C08]
 
 
NCT03002389: Hyperpolarized Xenon-129 MRI: a New Multi-dimensional Biomarker to Determine Pulmonary Physiologic Responses to COPD Therapeutics

Active, not recruiting
2
95
US
Anoro Ellipta, umeclidinium + vilanterol, Arnuity Ellipta, fluticasone
University of Virginia
Chronic Obstructive Pulmonary Disease
12/23
01/28
Trelegy Ellipta (fluticasone furoate/umeclidinium bromide/vilanterol) / GSK, Innoviva, Theravance Biopharma
NCT05535972: To Evaluate Real-World Effectiveness of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol (FF/UMEC/VI) in a Single Inhaler (Trelegy Ellipta) in Participants With Symptomatic COPD

Completed
4
463
Europe, RoW
FF/UMEC/VI, TRELEGY ELLIPTA
GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
09/23
09/23
Sundial-COPD, NCT05292053: Outcomes of Once-Daily ICS/LABA/LAMA Plus PRN Respiratory Therapy Treatments in Hospitalized Patients With COPD Exacerbations

Not yet recruiting
4
80
US
TRELEGY ELLIPTA 100Mcg-62.5Mcg-25Mcg/Actuation Powder for Inhalation
Baylor Research Institute
Copd
08/23
09/23
NCT06372496: Pragmatic Open - Label Randomized Clinical Trial of FF/UMEC/VI vs Non-ellipta Usual Care ICS-LABA for Adult Participants With Uncontrolled Asthma

Active, not recruiting
4
1358
Canada, Japan, US, RoW
Fluticasone furoate/umeclidinium bromide/vilanterol trifenatate, Inhaled corticosteroids/long-acting beta-2 agonists
GlaxoSmithKline
Asthma
09/25
03/26
NCT04923347: A Study to Evaluate the Safety and Efficacy of Fluticasone Furoate (FF)/Umeclidinium(UMEC)/Vilanterol (VI) in Participants With Chronic Obstructive Pulmonary Disease (COPD)

Completed
4
229
RoW
FF/UMEC/VI, ELLIPTA
GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
03/24
03/24
NCT06905483: Comparative Effects of Triple Inhaled Therapy With Budesonide/Glycopyrronium/Formoterol Versus Fluticasone Furoate/Umeclidinium/Vilanterol on Small Airway Disease in COPD Patients: A Randomized Crossover Study

Recruiting
4
28
RoW
Budesonide/Glycopyrronium/Formoterol (BGF), Breztri, Fluticasone Furoate/Umeclidinium/Vilanterol (FUV), Trelegy
Thammasat University
COPD, Chronic Obstructive Pulmonary Disease (COPD), Small Airway Disease, Triple Therapy, Lung Function
12/25
03/26
2013-003075-35: A 12 month study to compare FF/UMEC/VI with FF/VI and UMEC/VI in patients with Chronic Obstructive Pulmonary Disease(COPD) and a history of COPD exacerbation

Ongoing
3
1000
Europe, RoW
Fluticasone Furoate/Umeclidinium/Vilanterol Trifenatate, Fluticasone Furoate/Vilanterol Trifenatate, Umeclidinium/Vilanterol Trifenatate, GSK2834425 (GW685698/GSK573719/GW642444), GW685698/GW642444, GSK573719/GW642444, Relvar Ellipta, Relvar Ellipta
GlaxoSmithKline Research & Development Ltd, GlaxoSmithKline, S.A., GlaxoSmithKline, Research and Development Ltd
Chronic Obstructive Pulmonary Disease (COPD)
 
 
2013-003073-10: A 24 week study (with an extension to 52 weeks in a proportion of subjects) to compare the safety and effectiveness of FF/UMEC/VI with budesonide/formoterol in subjects with COPD Studio di 24 settimane (con estensione a 52 settimane in un sottogruppo di soggetti) per confrontare la sicurezza e l’efficacia di FF/UMEC/VI vs. budesonide/formoterolo in soggetti con broncopneumopatia cronica ostruttiva.

Ongoing
3
200
Europe
Fluticasone Furoate/Umeclidinium/Vilanterol, SALBUTAMOLO, GSK2834425, SB-240563, Symbicort Turbohaler 400 micrograms/12 micrograms/inhalation, inhalation powder, VENTOLIN SOSP INAL 200D 100MCG, Symbicort Turbohaler 400 micrograms/12 micrograms/inhalation, inhalation powder, VENTOLIN SOSP INAL 200D 100MCG
GlaxoSmithKline Research and Development, GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
 
 
2017-001532-19: An open-label study to compare the effectiveness of FF/UMEC/VI using the Connected Inhaler System with FP/SAL plus tiotropium in participants with inadequately controlled asthma

Not yet recruiting
3
1006
Europe
Fluticasone Furoate/Umeclidinium/Vilanterol, (Seretide Accuhaler/DISKUS), Spiriva Respimat, GW685698/GSK573719/GW642444, R03AK06, Inhalation powder, pre-dispensed, Inhalation solution, Trelegy Ellipta, Seretide Accuhaler/Diskus, 250/50 mcg or 500/50mcg, Spiriva Respimat
GlaxoSmithKline Research & Development Ltd, GSK
Inadequately controlled asthma, Inadequately controlled asthma, Diseases [C] - Respiratory Tract Diseases [C08]
 
 
ETHA, NCT04651777: Evaluation of Triple Therapy Using Magnetic Resonance Imaging in Asthma

Active, not recruiting
3
31
Canada
FF/UMEC/VI, Trelegy
Dr. Grace Parraga, GlaxoSmithKline
Asthma
08/23
12/24
Xerava (eravacycline) / SOM Biotech, Ewha Womans University, PAION, Innoviva
TheraCRAB, NCT06440304: Therapeutic Options for CRAB

Recruiting
4
108
RoW
Fosfomycin, Fosfomycin with Colistin, Eravacycline, Eravacycline with Colistin, ampicillin/sulbactam, Ampicilin/sulbactam with Colistin
Clinical Hospital Centre Zagreb
Infections, Bacterial, Sepsis Bacterial
12/26
02/27
TREAT-GNB, NCT07004049: Optimising TREATment for Severe Gram-Negative Bacterial Infections

Recruiting
4
600
Europe, RoW
Colistin/Polymyxin B + Sulbactam, Colistin/Polymyxin B + Tigecycline/Eravacycline, Colistin/Polymyxin B + Meropenem, Ceftazidime-avibactam + Sulbactam, Ceftazidime-avibactam + Fosfomycin, Ceftazidime-avibactam, Ceftazidime-avibactam + Aztreonam, Ceftazidime-avibactam + Colistin/Polymyxin B, High-dose meropenem, Meropenem + Fosfomycin, Meropenem-vaborbactam, Cefiderocol, Ceftolozane-tazobactam, Ceftolozane-tazobactam + Meropenem
National University of Singapore, The University of Queensland, European Clinical Research Alliance for Infectious Diseases (ECRAID)
Bloodstream Infection, Ventilator Associated Bacterial Pneumonia, Hospital Acquired Bacterial Pneumonia, Carbapenem Resistant Bacterial Infection, Multidrug Resistance
12/28
12/28
ChiCTR2400087137: A study on the pharmacokinetic characteristics and penetration of Eravacycline in the pulmonary bronchial fluid of adult patients with hospital-acquired pneumonia or ventilator-associated pneumonia

Not yet recruiting
4
16
 
Eravacycline Hydrochloride for Injection; Eravacycline Hydrochloride for Injection; Eravacycline Hydrochloride for Injection; Eravacycline Hydrochloride for Injection
Huashan Hospital, Fudan University; Huashan Hospital, Fudan University, Funded by Everest Medicines for this IIT study
HAP or VAP
 
 
ChiCTR2500098643: An exploratory study on the efficacy of eravacycline in CRKP infection

Not yet recruiting
4
60
 
Elacycline combine with other commonly used clinical fungicides (such as meropenem, polycolistin E, polymyxin B, levofloxacin, ceftazobactam, piperac; Tigacycline combine with other commonly used clinical fungicides (such as meropenem, polycolistin E, polymyxin B, levofloxacin, ceftazo
Shanghai tenth People's Hospital; Shanghai tenth People's Hospital, Self-funded project
Intraperitoneal infection, bloodstream infection, pulmonary infection, urinary infection
 
 
ChiCTR1900022060: A Phase 3, Randomized, Multicenter, Double-Blind, Double-Dummy, Parallel-Group, Comparative Study to Assess the Efficacy, Safety and Tolerability of Eravacycline Versus Ertapenem in the Treatment of Complicated Intra-Abdominal Infections (cIAI) in Hospitalized Adults

Completed
3
160
 
Eravacycline 1.0 mg/kg IV q 12h ;Ertapenem 1g IV q 24h
West China Hospital, Sichuan University; Everest Medicines (US) Limited, Fully founded by sponsor
Complicated intra-abdominal infections
 
 
ChiCTR2300078646: Efficacy and safety of eravacycline for complicated intra-abdominal infections in the ICU: A multicenter, single-blind, parallel randomized controlled trial study

Recruiting
3
292
 
Intravenous eravacycline; Intravenous tigecycline
Ansteel Group General Hospital; Ansteel Group General Hospital, Health Development Promotion Project of Beijing Health Alliance Charitable Foundation
Complicated intra-abdominal infections
 
 
ChiCTR2200055666: A Phase II/III, Randomized, Two-stage Clinical Study to Assess the Efficacy, Safety and Tolerability of Eravacycline Versus Moxifloxacin in the Treatment of Community-acquired Bacterial Pneumonia (CABP) in Adult Subjects

Recruiting
2/3
520
 
Elacycline 1.0 mg/kg IV q 12 h ;Two doses of eracycline 1.5 mg/kg IV were administered 12 hours apart (q12h). From the second day to the end of treatment (the third dose to the final dose), elacycline was 1.5 mg/kg, q24h ;Elacycline (dose and frequency determined in Stage 1) ;Moxifloxacin 0.4 g IV q24h
China-Japan Friendship Hospital; Everest Medicines (US) Limited, self-funded
Community-acquired Bacterial Pneumonia
 
 
NCT06794541: A Study to Evaluate the Safety and Tolerability of Eravacycline in Pediatric Patients Aged 8 to 17 With Complicated Intra-abdominal Infections (cIAI)

Recruiting
2
35
US
Eravacycline 2mg/kg, Eravacycline 1.5mg/kg
Innoviva Specialty Therapeutics, Tetraphase Pharmaceuticals, Inc.
Complicated Intra-abdominal Infections (cIAI)
03/29
03/29
NCT05537896: Prospective Evaluation of Xerava Prophylaxis in Hematological Malignancy Patients With Prolonged Neutropenia

Recruiting
2
55
US
Eravacycline, Xerava
West Virginia University
Hematological Malignancy, Neutropenia
02/28
02/28
ChiCTR1900022906: A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Pharmacokinetics, Safety and Tolerability of Single-dose and Multiple-dose Intravenous Infusion of Eraracycline in Chinese Healthy Subjects

Completed
1
28
 
Eravacycline 0.5 mg/kg IV single dose ;Single dose: Eravacycline 1 mg/kg IV; Multiple dose: Eravacycline 1 mg/kg IV q12h, 10 days ;Eravacycline 2 mg/kg IV single dose
Huashan Hospital Affiliated to Fudan University; Everest Medicines (US) Limited, Fully founded by sponsor
Not applicable
 
 
NCT06282835: Eravacycline Combination Therapy for MRAB

Recruiting
N/A
20
RoW
Eravacycline Injection
Fujian Medical University Union Hospital
Pulmonary Infection, Pneumonia, Bacterial, Acinetobacter Baumannii
10/24
12/24
NCT06223100: Efficacy and Safety of the Combination Therapy Based on Eravacycline in Immunocompromised Hosts With MDROS Infection

Not yet recruiting
N/A
100
NA
Eravacycline, XERAVA
Sichuan Provincial People's Hospital
Immune Dysregulation Disorder
12/25
12/25
NCT06670872: A Study on the Combination Therapy of Eravacycline for Treating Carbapenem-Resistant Acinetobacter Baumannii Pneumonia

Not yet recruiting
N/A
50
RoW
Eravacycline combination therapy group
Peking University Third Hospital
Pneumonitis, Acinetobacter Baumannii
10/25
10/26
NCT06666998: Real-World Pharmacokinetic/Pharmacodynamic Study of Eravacycline in Critically III Patients

Not yet recruiting
N/A
100
NA
Sichuan Provincial People's Hospital
Eravacycline, Pharmacokinetics, Bacteria Infection, Bacterial Resistance to Antimicrobial, Empirical Antimicrobial Therapy
11/26
11/26
ChiCTR2400089338: The efficacy and safety observation study of Eravacycline treatment in patients with neutropenia and fever: A multicenter retrospective cohort study based on HIS data

Not yet recruiting
N/A
200
 
Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing Life Oasis Public Service Center
Granulocyte deficiency with fever
 
 
ChiCTR2400083038: A real-world study of the clinical use of eravacycline

Recruiting
N/A
50
 
None
Huashan hospital; Huashan hospital, Beijing Life Oasis public Service Center
Bacterial Infection
 
 
ChiCTR2500103344: Retrospective Study on the Efficacy and Safety of Eravacycline Based on Real-world Data

Not yet recruiting
N/A
300
 
NA
Sun Yat-sen Memorial Hospital, Sun Yat-sen University; Sun Yat-sen Memorial Hospital, Sun Yat-sen University, None
Patients clinically diagnosed with infections (including pulmonary infections, skin/soft tissue infections, intra-abdominal infections, bloodstream infections, etc.).
 
 
ChiCTR2500096976: Synergistic Mechanisms of Eravacycline Combined with Aminoglycosides in the Treatment of CRE Infections: A Single-Arm Clinical Study and Integrated Multi-Omics Analysis

Not yet recruiting
N/A
9
 
SUN YAT-SEN MEMORIAL HOSPITAL; SUN YAT-SEN MEMORIAL HOSPITAL, Primary Health Care Foundation of China
CRE infection
 
 
Xacduro (sulbactam-durlobactam) / Innoviva
NCT06801223: A Study to Assess Sulbactam-durlobactam in Pediatric Patients With Acinetobacter Baumannii-calcoaceticus Complex Infection

Recruiting
1
48
US
Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 6 hours), SUL-DUR, Sulbactam 20mg/kg-Durlobactam 20mg/kg (Every 8 hours), Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 8 hours), Sulbactam 20mg/kg-Durlobactam 20mg/kg (Every 12 hours)
Innoviva Specialty Therapeutics, Entasis Therapeutics
Acinetobacter Baumannii-calcoaceticus Complex Infection (ABC)
05/28
05/28
NCT06746883: A Study to Assess the Safety and Risk of Hypersensitivity Reactions of Sulbactam-durlobactam in Adults With Acinetobacter Baumannii-calcoaceticus (ABC) Complex Infection

Recruiting
N/A
100
US
Non-interventional
Innoviva Specialty Therapeutics
Acinetobacter Baumannii-calcoaceticus Complex Infection (ABC)
01/29
01/29
LJPC-401 / Innoviva
No trials found
LJP 1207 / Innoviva
No trials found
ETX1317 / Innoviva
No trials found
allopregnanolone (LJPC-0712) / Innoviva
No trials found
TP-2846 / Innoviva
No trials found
artesunate (LJPC-0118) / Innoviva
No trials found
cefpodoxime/ETX 1317 / Innoviva
No trials found

Download Options